• patients
  • The success of some of the current cancer immunotherapy approaches in oncological patients depends on the intrinsic antigenicity of each tumor as has recently been disclosed, and it is hampered in those patients that are treated with myeloablative chemotherapy or radiotherapy, which induce profound immunosuppression. (cun.es)
  • This randomized phase III multicenter study was designed with 3 arms, comparing 2 calcineurin inhibitor (CNI)-free strategies for graft-versus-host disease (GVHD) prophylaxis to standard tacrolimus and methotrexate in patients with hematologic malignancies who are also undergoing myeloablative conditioning hematopoietic stem cell transplantation. (onclive.com)